Mirikizumab and Tirzepatide Trial
Phase 3
350
about 2.8 years
18–70
37 sites in AL, CA, FL +20
What this study is about
Researchers are testing whether a combination of mirikizumab and tirzepatide, compared to mirikizumab alone, helps reduce or eliminate symptoms of ulcerative colitis (UC) in adults with UC and obesity. The trial will last up to 61 weeks, including 52 weeks of treatment.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Mirikizumab
- 2.Take Placebo
- 3.Take Tirzepatide
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
You may get a placebo/standard care, and you won't know which.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
mirikizumab, tirzepatide
injection (Injection)
Secondary: Percentage of Participants Who Achieve Bowel Movement Urgency Improvement Captured with Urgency Numeric Rating Scale (NRS)
Endocrinology, Gastroenterology